Palliative Chemotherapy
Palliative chemotherapy aims to improve quality of life, control symptoms, and extend survival in patients with incurable cancer, requiring careful balance of benefit against treatment toxicity.
Key Facts
- Palliative chemotherapy aims to improve quality of life and extend survival; it is not curative
- Patient performance status (ECOG 0-2) is the most important factor determining suitability for palliative chemo
- Median survival benefit varies widely: weeks to months depending on cancer type and regimen
- Quality of life assessment should be integral to treatment decisions; validated tools include EORTC QLQ-C30
- Treatment breaks/holidays are appropriate and increasingly recognised as valuable for patients
- Shared decision-making is essential: patients must understand treatment intent, expected benefits, and side effects
- NICE recommends against chemotherapy in patients with ECOG PS ≥3 (limited benefit, high toxicity risk)
- Advance care planning should be discussed alongside palliative chemotherapy decisions
Overview
Key Facts
Palliative chemotherapy is a cornerstone of cancer care but requires careful patient selection and honest communication about goals and limitations.
Epidemiology
- Approximately 50% of chemotherapy given in the UK is with palliative intent
- Treatment-related mortality from palliative chemo: approximately 2-3%
- SACT 30-day mortality is a national quality indicator (target <8%)
Aetiology
Palliative chemotherapy is indicated for incurable/metastatic cancers where treatment may improve symptoms and extend life.
Pathophysiology
- Same mechanisms as curative chemotherapy (DNA damage, cell cycle disruption)
- Lower dose intensities and less aggressive regimens may be used to balance efficacy and toxicity
- Treatment breaks allow recovery and maintain quality of life
- Immunotherapy and targeted therapies increasingly used in the palliative setting with potentially fewer side effects than cytotoxic chemotherapy
Clinical Presentation
Indications for Palliative Chemotherapy
- Symptom control (e.g. pain from tumour, dyspnoea, bleeding)
- Disease control (slow progression, prevent complications)
- Survival extension
- Patient preference (desire to "do something")
Assessment Before Treatment
- Performance status (ECOG 0-2 generally required)
- Organ function (renal, hepatic, cardiac, bone marrow)
- Nutritional status
- Patient understanding and expectations
- Goals of care discussion
Red Flags Indicating Treatment May Not Be Appropriate
- ECOG PS ≥3
- Severe organ dysfunction
- Recent acute illness or infection
- Patient ambivalence or lack of understanding about palliative intent
- Rapidly deteriorating condition
- Less than 3 months predicted survival (for most regimens)
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| Treatment toxicity | Side effects mimicking disease progression | Clinical assessment, bloods |
| Disease progression | Rising markers, new symptoms, imaging progression | Restaging CT/PET |
| Concurrent illness | Infection, PE, cardiac event | Appropriate investigations |
| Depression/fatigue | May mimic poor performance status | Psychological assessment |
Diagnosis / Investigation
Bedside
- Performance status assessment (ECOG/Karnofsky)
- Weight, BMI, nutritional assessment
- Quality of life assessment (EORTC QLQ-C30)
Bloods
- FBC, U&Es, LFTs (organ function; assess before each cycle)
- GFR (for dose calculations, especially platinum agents)
- Tumour markers (monitoring response)
- Albumin (nutritional/prognostic marker)
Imaging
- Restaging CT typically every 3-4 cycles (RECIST criteria)
- Response: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)
Special Tests
- Quality of life questionnaires
- Holistic needs assessment
- DPYD testing before fluoropyrimidines
- Echocardiography if using cardiotoxic agents
Management
Non-pharmacological
- Shared decision-making: ensure patient understands palliative intent
- Goals of care discussions (what matters most to the patient)
- Advance care planning: discuss alongside treatment decisions
- Treatment breaks: acceptable and may improve quality of life without worsening outcomes
- Nutritional support
- Psychological support
- Palliative care involvement (not just at end of life)
Pharmacological
- Regimen selection based on: cancer type, molecular profile, performance status, comorbidities, patient preference
- Common palliative regimens: single-agent or reduced-intensity combinations
- Supportive care: antiemetics, G-CSF if indicated, growth factors
- Dose modifications based on toxicity
- Treatment duration: typically continued until progression or intolerable toxicity
Surgical/Interventional
- Not specifically related to palliative chemotherapy
- Palliative procedures may be used alongside (stenting, drainage, RT)
Referral Criteria
- All patients receiving palliative chemotherapy: regular oncology review
- Deteriorating performance status: reassess treatment appropriateness
- Palliative care referral: concurrent with palliative chemotherapy (early referral improves outcomes - Temel 2010 NEJM)
- Treatment toxicity: acute oncology assessment
Prognosis
- Varies enormously by cancer type and regimen:
- Metastatic CRC (FOLFOX + biological): median OS 25-30 months
- Metastatic NSCLC (immunotherapy): median OS 15-25 months
- Metastatic pancreatic (mFOLFIRINOX): median OS 11 months
- Benefit must be weighed against toxicity for each individual
- SACT 30-day mortality: approximately 3-8% depending on regimen
- Concurrent palliative care improves quality of life and may extend survival (Temel et al. 2010)
- Many patients overestimate the survival benefit of palliative chemotherapy
Other Relevant Information
ECOG Performance Status and Treatment Suitability
| ECOG | Description | Palliative Chemo Suitability |
|---|---|---|
| 0 | Fully active | Yes |
| 1 | Restricted strenuous activity | Yes |
| 2 | Ambulatory, self-caring, up >50% | Consider (reduced intensity) |
| 3 | Limited self-care, >50% in bed/chair | Generally not appropriate |
| 4 | Completely disabled | Not appropriate |
SACT 30-Day Mortality (NHS England Quality Indicator)
| Metric | Target |
|---|---|
| 30-day mortality after curative chemo | <1% |
| 30-day mortality after palliative chemo | <8% |
| Chemotherapy in last 30 days of life | Minimise (quality indicator) |